SOURCE: Pharming Group N.V.

June 07, 2007 04:28 ET


LEIDEN, NETHERLANDS--(Marketwire - June 7, 2007) -

Leiden, The Netherlands, June 7, 2007. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) today announced that the founders of its subsidiary DNage have published new insights in the field of aging in the leading scientific journal Nature.


Professor Irving Weissman and his team at Stanford University (CA, USA) together with DNage's scientific founder professor Jan Hoeijmakers of the Erasmus Medical Center (Rotterdam, NL) have shown, using of one DNage's mouse models, that accumulation of DNA damage progressively limits functional capacity of stem cells. This finding is very important in a number of ways: firstly, it strengthens the link between DNA damage and ageing. Secondly, it establishes a clear model on how the accumulation of DNA damage leads to ageing of tissues and organs. Thirdly, these data further support the suitability of our proprietary mouse models in ageing and stem cell research. Finally, the findings provide Pharming with clear angles on how to approach the treatment or prevention of ageing diseases. This insight is currently being applied to develop novel approaches for treatment of osteoporosis and neurodegeneration.

Background on the principal authors

Jan Hoeijmakers, PhD is the head of the department of Genetics at the Erasmus Medical Center in Rotterdam. His work focuses for the past twenty-five years on DNA damage and repair. He and his team were the first to clone a DNA repair gene in the early 80's, have generated an extensive collection of mouse models and were also the first that established the link between DNA damage accumulation and ageing. In 2004 Jan Hoeijmakers co-founded DNage based on these findings. Irving Weissman, PhD, is the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, Palo Alto, California, US. Prof Weissman is one of the leading experts worldwide in the field of stemcell biology. He has been active in this field for more than 30 years and is considered to be one of the founders of the field of adult stem cell biology. Dr. Weissman is also the founder of several companies including Systemix, a successful biotech company in the field of stemcells which was sold to Novartis in the 90's.

Background on Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its subsidiary DNage). Additional information is available on the Pharming website, and on

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Carina Hamaker              Rein Strijker
Investor Voice              Pharming Group NV
T: +31 (0)6 537 499 59      T: +31 (0)71 52 47 400
T: +31 (0)71 52 47 400

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information